Kidney Disease News
-
NICE Irreversible Electroporation for Treating Prostate Cancer Announcement
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute ...
-
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
By Bayer AG
-
New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...
By Bayer AG
-
INCOGEN Completes NIH Funded BISTI Project
INCOGEN and its collaborators announced the completion of the five-year long clear cell renal cell carcinoma (ccRCC) project. This multidisciplinary project was funded by several National Cancer Institute Small Business Innovation Research (SBIR) grants and involved collaborations with the Mayo Clinic, Eastern Virginia Medical School, and Johns Hopkins University. It resulted in the development ...
-
INCOGEN Presents at BioPharma Asia and PepCon
INCOGEN will present two invited talks at the BioPharma Asia conference in Singapore and the PepCon conference in Beijing, China. The presentations will describe recent progress of our NCI-funded renal cancer project conducted in collaboration with Mayo Clinic, Eastern Virginia Medical School, and Johns Hopkins University. ...
-
Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
By Bayer AG
-
SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times
SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS). The program involved using Oxford Nanopore’s ...
-
Kidney and Pancreas Function Diagnostic Enzymes Are Now Available at Creative Enzymes
Creative Enzymes, a global leader in diagnostic enzyme manufacturing and supply, is dedicated to offering a wide range of enzyme products as well as customized enzyme-related services for medical and research diagnosis. Recently, Creative Enzymes launched kidney and pancreas function diagnostic enzymes for the global market. The primary function of the kidney is to eliminate waste and excess ...
-
Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma ...
-
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
-
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
By Bayer AG
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a ...
-
Apollo Medical Holdings, Inc. Receives NCQA`s HEDIS Health Plan Measure Certification for Measurement Year 2022
Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that ApolloMed received certification from the National Committee for Quality Assurance ("NCQA") for ...
-
Creative Enzymes Launches Raw Materials for Manufacturing Diagnostic Kits
Creative Enzymes, a worldwide leading company in diagnostic enzymes manufacturing and supply, is committed to providing customers with diverse enzyme products and custom enzyme-related services for medical and research diagnosis. Recently, Creative Enzymes launched the raw materials for manufacturing Diagnostic Kits. The raw materials provided by Creative Enzymes include enzymes for cholesterol ...
-
Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) and Nanna Lüneborg, PhD, MBA, General Partner at Forbion. “It is with great pleasure that I ...
-
Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market
Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D., will join the company’s scientific advisory board. Dr. Chandra is board certified in both general and vascular surgery. She is a clinical associate professor of surgery in the Division of Vascular Surgery at Stanford University ...
-
1st Successful Heart Tumor Removal Without Open Heart Surgery
EchoPixel has once again contributed to a pioneering procedure at CentraCare – St. Cloud Hospital with the first team to remove a heart tumor without invasive open heart surgery using the novel AlphaVac catheter. Previously CentraCare had been the first to use EchoPixel’s 4D hologram technology to conduct the WATCHMAN implant, which is a one-time, minimally invasive procedure ...
-
Cancer Treatment is the USA: Methods, Top Clinics, Cost, Financing Options
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
-
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you